Cardiac Safety in the APHINITY trial

OVERVIEW

ESMO Open has published an article co-authored by a member of our Biostatistics team. Results of the exploratory analysis conclude that after >6 years of median follow-up, pertuzumab and trastuzumab did not increase cardiotoxicity risk compared to trastuzumab, and therefore, the analysis confirms the cardiac safety of adjuvant anti-HER2 treatment with pertuzumab and trastuzumab.

APHINITY was a randomised, double-blind, phase III study comparing the addition of pertuzumab or placebo to adjuvant trastuzumab and chemotherapy in patients with HER2-positive early breast cancer.

The APHINITY trial was supported by F. Hoffmann-La Roche Ltd/Genentech and was designed by the Breast International Group (BIG) in collaboration with the sponsor.

The database was maintained at the Institut Jules Bordet Clinical Trials Support Unit (Brussels, Belgium), and the statistical analyses were carried out by Frontier Science Scotland.

TITLE OF PUBLICATION

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial

AUTHORS

E. de Azambuja; E. Agostinetto; M. Procter; D. Eiger; N. Pondé; S. Guillaume; D. Parlier; M. Lambertini; A. Desmet; C. Caballero; C. Aguila; G. Jerusalem; J.M. Walshe; E. Frank; J. Bines; S. Loibl; M. Piccart-Gebhart; M.S. Ewer; S. Dent; C. Plummer; T. Suter; on behalf of the APHINITY Steering Committee and Investigators

Publication Reference

ESMO Open | Volume 8 | Issue 1 | 100772 | February 2023

MORE PUBLICATIONS FROM FRONTIER SCIENCE SCOTLAND

OlympiA results in the subset of patients from Japan

OlympiA results in the subset of patients from Japan

The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.

read more
APHINITY | European Journal of Cancer (EJC)

APHINITY | European Journal of Cancer (EJC)

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

read more
APHINITY | AACR Cancer Research

APHINITY | AACR Cancer Research

Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial.

read more